Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) traded down 4.5% during mid-day trading on Friday . The stock traded as low as $8.1950 and last traded at $8.22. 15,987 shares were traded during trading, a decline of 97% from the average session volume of 602,475 shares. The stock had previously closed at $8.61.
Athira Pharma Stock Performance
The company has a market cap of $32.42 million, a price-to-earnings ratio of -0.85 and a beta of 2.79. The company has a 50-day simple moving average of $9.55 and a 200-day simple moving average of $7.32.
Hedge Funds Weigh In On Athira Pharma
A number of hedge funds have recently bought and sold shares of the company. Focus Partners Wealth acquired a new position in Athira Pharma in the third quarter worth about $35,000. Jane Street Group LLC bought a new position in Athira Pharma in the fourth quarter worth about $100,000. Renaissance Technologies LLC lifted its holdings in Athira Pharma by 44.7% in the fourth quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after acquiring an additional 23,223 shares during the last quarter. Seven Fleet Capital Management LP bought a new position in Athira Pharma in the fourth quarter worth about $969,000. Finally, Millennium Management LLC bought a new position in Athira Pharma in the fourth quarter worth about $2,456,000. 57.12% of the stock is currently owned by institutional investors and hedge funds.
Athira Pharma Company Profile
Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).
The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.
Featured Articles
- Five stocks we like better than Athira Pharma
- Alphabet’s Most Overlooked Division Just Had a Big Week
- Cooking Up Profits: Cracker Barrel’s Turnaround
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
